FDA Grants AltruBio AbGn-168H (Neihulizumab) Fast Track Designation in SR-aGVHD
Initiate multiple dose phase study (Phase 1b) of AbGn-168H in patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD) in the United State.
Phase 2a anti-TNF α and/or anti-integrin refractory/intolerant Ulcerative Colitis trial completed with proof of Clinical efficacy achieved in the United States.
The Company changes its name to AltruBio Inc.
Complete single dose escalation, safety and initial efficacy in Phase 1a clinical trial study of AbGn-168H in patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD) in the United State.
Dr. Judy Chou, Joins the company as president & CEO.
FDA Grants AbGn-168H (Neihulizumab) Orphan Drug Designation in treating aGVHD.
Proof of initial efficacy was demonstrated in a Phase-2a clinical trial study of AbGn-168H in patients with psoriatic arthritis.
AbGn-168H’s phase-II clinical trial targeting psoriasis completed in the United States.
Phase 2a clinical trial of AbGn-168H in patients with psoriasis completed in the U.S.
Phase 1 clinical trial of AbGn-168H completed in healthy volunteers.
AbGenomics International Inc. (AbGUS) formed in the United States.
Patent application for AbGn-168 were filed with USPTO and WIPO, a monoclonal antibody for the frestment of multiple immunological diseases.